We are live on ! Find out more
PBPIA

Pivotal bioVenture Partners Investment Advisor Portfolio holdings

AUM $280M
1-Year Est. Return 181.4%
This Fund
S&P 500
This Quarter Est. Return
+28.29%
1 Year Est. Return
+181.4%
3 Year Est. Return
+730.97%
5 Year Est. Return
+1,157.4%
10 Year Est. Return
–
AUM
$173M
AUM Growth
+$11.6M
Cap. Flow
-$15.6M
Cap. Flow %
-9.01%
Top 10 Hldgs %
100%
Holding
13
New
1
Increased
2
Reduced
–
Closed
3

Top Buys

Rank Stock Value
1
IMNM icon
Immunome
IMNM
+$5M
2
PCVX icon
Vaxcyte
PCVX
+$2.23M
3
TRVI icon
Trevi Therapeutics
TRVI
+$830K

Top Sells

Rank Stock Value
1
INZY
Inozyme Pharma
INZY
+$18M
2
VIGL
Vigil Neuroscience
VIGL
+$4.46M
3
IOBT
IO Biotech
IOBT
+$1.2M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PCVX icon
1
Vaxcyte
PCVX
$8.81B
$49.4M 28.58%
1,372,425
+67,300
+5% +$2.23M
OCS icon
2
Oculis Holding
OCS
$708M
$40.4M 23.38%
2,300,774
– –
ARQT icon
3
Arcutis Biotherapeutics
ARQT
$3.3B
$40M 23.11%
2,120,508
– –
ZBIO
4
Zenas BioPharma
ZBIO
$2.05B
$17.3M 10%
779,045
– –
TRVI icon
5
Trevi Therapeutics
TRVI
$2.54B
$11.5M 6.65%
1,256,782
+110,672
+10% +$830K
IMNM icon
6
Immunome
IMNM
$2.97B
$5.88M 3.4%
+502,512
New +$5M
BIOA
7
BioAge Labs
BIOA
$490M
$3.84M 2.22%
653,374
– –
RXRX icon
8
Recursion Pharmaceuticals
RXRX
$1.8B
$2.91M 1.68%
595,518
– –
RLYB icon
9
Rallybio
RLYB
$87M
$1.2M 0.69%
300,581
– –
BOLT icon
10
Bolt Biotherapeutics
BOLT
$7.65M
$503K 0.29%
94,573
– –
INZY
11
DELISTED
Inozyme Pharma
INZY
– –
-4,494,851
Closed -$18M
IOBT
12
DELISTED
IO Biotech
IOBT
– –
-864,197
Closed -$1.2M
VIGL
13
DELISTED
Vigil Neuroscience
VIGL
– –
-560,595
Closed -$4.46M

Similar funds

HCM
Hall Capital Management Barrington, Rhode Island $280M AUM 14.82% 1-Year Est. Return
OFCM
One Fin Capital Management San Francisco, California $280M AUM 49.87% 1-Year Est. Return
NCM
NCM Capital Management Ramsey, New Jersey $279M AUM 26.47% 1-Year Est. Return
CCC
Compass Capital Corp Braintree, Massachusetts $279M AUM 28.36% 1-Year Est. Return
PHC
Panoramic Hills Capital Road Town $280M AUM
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
SL
SOF Ltd George Town, Cayman Islands $279M AUM 6.12% 1-Year Est. Return
CC
Checkpoint Capital San Francisco, California $279M AUM 45.74% 1-Year Est. Return

Pivotal bioVenture Partners Investment Advisor's Q3 2025 Portfolio in Review

As of Q3 2025, Pivotal bioVenture Partners Investment Advisor held 13 positions worth $173M, up 7.2% from $161M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Pivotal bioVenture Partners Investment Advisor withdrew a net $15.6M in Q3 2025, closing 3 positions. Its most notable exit was Inozyme Pharma, an estimated $18M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Pivotal bioVenture Partners Investment Advisor opened a new position in Immunome worth $5.88M.

  • Pivotal bioVenture Partners Investment Advisor's largest Q3 2025 buy was Immunome: 502,512 shares worth $5.88M.
  • Pivotal bioVenture Partners Investment Advisor added most to Vaxcyte in Q3 2025, an estimated $2.23M increase.
  • Pivotal bioVenture Partners Investment Advisor fully exited Inozyme Pharma in Q3 2025, selling an estimated $18M.
  • Pivotal bioVenture Partners Investment Advisor's ten largest holdings make up 100% of its $173M portfolio in Q3 2025.
  • Pivotal bioVenture Partners Investment Advisor opened 1 new position and closed 3 in Q3 2025.
  • Pivotal bioVenture Partners Investment Advisor's portfolio value rose 7.2% quarter-over-quarter to $173M.

Based on Pivotal bioVenture Partners Investment Advisor's 13F filing for Q3 2025, filed 13 Nov 2025.